Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Tarsus Pharmaceuticals, with four buy ratings, two strong-buy ratings, two holds and one sell. The average 12-month price target is $90.50, versus a reported share price of $69.20.
• Tarsus reported quarterly revenue of $173.91 million, exceeding estimates of $169.65 million, but its loss of $0.43 per share was wider than the expected $0.19 loss. Analysts project a full-year loss of $2.06 per share.
• Insiders sold 39,850 shares worth approximately $2.45 million over the past 90 days, while institutional investors own a substantial 90.01% of the company. Tarsus is focused on ophthalmic therapies, including its lead dry-eye treatment candidate OC-01.

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $90.50.

TARS has been the subject of a number of analyst reports. Mizuho cut their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. HC Wainwright reaffirmed a "buy" rating and issued a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Finally, Guggenheim cut their price target on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating for the company in a report on Tuesday, July 21st.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 12,500 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $62.12, for a total transaction of $776,500.00. Following the transaction, the director owned 106,786 shares in the company, valued at approximately $6,633,546.32. The trade was a 10.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $61.55, for a total value of $615,500.00. Following the transaction, the chief executive officer directly owned 847,991 shares of the company's stock, valued at approximately $52,193,846.05. This trade represents a 1.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 39,850 shares of company stock worth $2,452,821. Company insiders own 9.64% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TARS. Parallel Advisors LLC lifted its holdings in Tarsus Pharmaceuticals by 139.2% in the first quarter. Parallel Advisors LLC now owns 500 shares of the company's stock valued at $35,000 after acquiring an additional 291 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Tarsus Pharmaceuticals by 367.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock worth $50,000 after purchasing an additional 558 shares during the period. Comerica Bank grew its stake in shares of Tarsus Pharmaceuticals by 470.0% during the 4th quarter. Comerica Bank now owns 855 shares of the company's stock worth $70,000 after purchasing an additional 705 shares during the period. Truvestments Capital LLC increased its holdings in shares of Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company's stock valued at $74,000 after purchasing an additional 468 shares in the last quarter. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock valued at $105,000 after purchasing an additional 172 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Trading Up 0.5%

NASDAQ:TARS opened at $69.20 on Friday. Tarsus Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $85.25. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21. The stock's 50 day simple moving average is $62.41 and its 200-day simple moving average is $64.89. The firm has a market cap of $3.04 billion, a P/E ratio of -63.49 and a beta of 0.53.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The company had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. Equities analysts anticipate that Tarsus Pharmaceuticals will post -2.06 EPS for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source